Aethlon Medical, Inc. (NASDAQ:AEMD) Sees Significant Increase in Short Interest

Aethlon Medical, Inc. (NASDAQ:AEMD) was the target of a large increase in short interest in the month of May. As of May 15th, there was short interest totaling 28,844 shares, an increase of 105.3% from the April 30th total of 14,050 shares. Based on an average trading volume of 59,037 shares, the short-interest ratio is currently 0.5 days. Currently, 1.9% of the shares of the company are short sold.

Institutional Investors Weigh In On Aethlon Medical

A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC acquired a new position in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 36.57% of Aethlon Medical at the end of the most recent reporting period. 1.99% of the stock is currently owned by hedge funds and other institutional investors.

Aethlon Medical Stock Up 3.8%

Shares of AEMD traded up $0.09 during midday trading on Monday, reaching $2.30. 341,378 shares of the stock were exchanged, compared to its average volume of 344,442. The stock’s 50 day simple moving average is $2.24 and its 200 day simple moving average is $2.62. The company has a market cap of $3.60 million, a P/E ratio of -0.16 and a beta of 1.49. Aethlon Medical has a twelve month low of $1.36 and a twelve month high of $30.40.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a research report on Monday, April 20th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Reduce”.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.